A- A A+

Opioid Use Disorder: Treatments and Barriers. 

Patel K, Bunachita S, Agarwal AA, Lyon A, Patel UK. 

Cureus. 2021 Feb 6;13(2):e13173. doi: 10.7759/cureus.13173. PMID: 33717718; PMCID: PMC7938868.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938868/

Frequency of health-care utilization by adults who use illicit drugs: a systematic review and meta-analysis. 

Lewer D, Freer J, King E, Larney S, Degenhardt L, Tweed EJ, Hope VD, Harris M, Millar T, Hayward A, Ciccarone D, Morley KI. 

Addiction. 2020 Jun;115(6):1011-1023. doi: 10.1111/add.14892. Epub 2020 Feb 10. PMID: 31705770; PMCID: PMC7210080.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210080/

Findings from the recovery initiation and management after overdose (RIMO) pilot study experiment. 

Scott CK, Dennis ML, Grella CE, Nicholson L, Sumpter J, Kurz R, Funk R. 

J Subst Abuse Treat. 2020 Jan;108:65-74. doi: 10.1016/j.jsat.2019.08.004. Epub 2019 Aug 7. PMID: 31493942; PMCID: PMC6893133.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893133/

Palliative care for people with substance use disorder and multiple problems: a qualitative study on experiences of patients and proxies. 

Ebenau A, Dijkstra B, Ter Huurne C, Hasselaar J, Vissers K, Groot M. 

BMC Palliat Care. 2019 Jul 12;18(1):56. doi: 10.1186/s12904-019-0443-4. PMID: 31299956; PMCID: PMC6626397.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626397

Considering the harms of our habits: The reflexive urine drug screen in opioid use disorder treatment

Khatri, Utsha G. et al.

Journal of Substance Abuse Treatment, Volume 123, 108258 

Abstract

https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(20)30515-8/fulltext

USA. Illinois Methadone Patients Could Be First to Have Privacy Rolled Back After SAMHSA Rule-Change

An Illinois Senator appears to be the first state lawmaker to push for a bill that would make a controversial federal rollback of opioid use disorder patients’ privacy rights mandatory at the state level. (Filter, USA, 29.03.2021)

https://filtermag.org/illinois-methadone-privacy-samhsa/

USA. Progress of Four Programs from the Comprehensive Addiction and Recovery Act. 

National Academies of Sciences, Engineering, and Medicine 2021. Washington,DC: The National Academies Press. doi.org/10.17226/26060.

file:///Users/hans/Downloads/26060.pdf

Caring for people who inject drugs when they are admitted to hospital

Thomas D. Brothers, John Fraser, Duncan Webster

CMAJ Mar 2021, 193 (12) E423-E424; DOI: 10.1503/cmaj.202124 

https://www.cmaj.ca/content/193/12/E423

USA. What are the barriers to starting and maintaining a program of medication treatment in healthcare settings?

Opioid use disorder (OUD) medications are effective life-saving treatments that help support recovery. However, only about one-third of addiction treatment organizations offer any medication for OUD treatment. This study assessed barriers to newly implementing and delivering medication treatment, including practical barriers as well as negative attitudes and stigma toward medication treatment. (Recovery Research Institute, USA, 22.03.2021)

https://www.recoveryanswers.org/research-post/barriers-to-starting-maintaining-program-medication-treatment-healthcare-settings/

Changes in opioid-related deaths following increased access to opioid substitution treatment. 

Andersson L, Håkansson A, Berge J, Johnson B. 

Subst Abuse Treat Prev Policy. 2021 Feb 10;16(1):15. doi: 10.1186/s13011-021-00351-4. PMID: 33568184; PMCID: PMC7876792.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876792/

Facilitators and Barriers to Nurse Practitioners Prescribing Methadone for Opioid Use Disorder in Nova Scotia: A Qualitative Study. 

Bates AE, Martin-Misener R. 

Can J Nurs Res. 2021 Feb 20:844562121996222. doi: 10.1177/0844562121996222. Epub ahead of print. PMID: 33615847.

https://journals.sagepub.com/doi/10.1177/0844562121996222

Supportive alternate site provision of buprenorphine: Overcoming barriers and improving patient outcomes. 

Khan A, Khan Q, Kolb E. 

J Subst Abuse Treat. 2021 Apr;123:108256. doi: 10.1016/j.jsat.2020.108256. Epub 2020 Dec 18. PMID: 33612191.

https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(20)30513-4/fulltext

Creation of an algorithm for clinical decision support for treatment of opioid use disorder with buprenorphine in primary care. 

Dela Cruz AM, Walker R, Pipes R, Wakhlu S, Trivedi MH.

Addict Sci Clin Pract. 2021 Feb 19;16(1):12. doi: 10.1186/s13722-021-00222-0. PMID: 33608060; PMCID: PMC7893913.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893913/

What Differs between Patients under Methadone and under Buprenorphine for Opioid Use Disorder (OUD) in Daily Clinical Practice in France? A Short Report. 

Guillou-Landreat M, Dany A, Challet-Bouju G, Laforgue E, Leboucher J, Benoit Hardouin J, Victorri-Vigneau C, Grall-Bronnec M. 

Int J Environ Res Public Health. 2021 Feb 3;18(4):1425. doi: 10.3390/ijerph18041425. PMID: 33546494; PMCID: PMC7913704.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913704/

Linking opioid use disorder treatment from hospital to community. 

Brothers, T. D., Lewer, D., and Thakrar, A. P. (2021) 

Addiction, doi.org/10.1111/add.15460. 

https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.15460

Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting. 

Dong H, Hayashi K, Milloy MJ, DeBeck K, Singer J, Wong H, Wood E, Kerr T.

Drug Alcohol Depend. 2020 Jul 1;212:108005. doi: 10.1016/j.drugalcdep.2020.108005. Epub 2020 Apr 25. PMID: 32370932; PMCID: PMC7462099.

Abstract

https://pubmed.ncbi.nlm.nih.gov/32370932/

Video-Counseling Intervention to Address HIV Care Engagement, Mental Health, and Substance Use Challenges: A Pilot Randomized Clinical Trial for Youth and Young Adults Living with HIV. 

Saberi P, McCuistian C, Agnew E, Wootton AR, Legnitto Packard DA, Dawson-Rose C, Johnson MO, Gruber VA, Neilands TB. 

Telemed Rep. 2021 Jan 7;2(1):14-25. doi: 10.1089/tmr.2020.0014. PMID: 33575683; PMCID: PMC7869821.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869821/

Outcomes for patients receiving telemedicine-delivered medication-based treatment for Opioid Use Disorder: A retrospective chart review. 

Weintraub E, Greenblatt AD, Chang J, Welsh CJ, Berthiaume AP, Goodwin SR, Arnold R, Himelhoch SS, Bennett ME, Belcher AM. 

Heroin Addict Relat Clin Probl. 2021;23(2):5-12. PMID: 33551692; PMCID: PMC7861202.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861202/

Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans. 

Eydt E, Glegg S, Sutherland C, Meador K, Trew M, Perreault M, Goyer MÈ, Le Foll B, Turnbull J, Fairbairn N. 

CMAJ Open. 2021 Feb 23;9(1):E115-E124. doi: 10.9778/cmajo.20200021. PMID: 33622764.

http://cmajopen.ca/content/9/1/E115.long

Kanada. How Canadian Drug Users Helped Save an Injectable Opioid Agonist Program

Amid a historic fatal overdose crisis, the Canadian province of Alberta wanted to end an opioid use disorder (OUD) treatment program that met the needs of patients for whom oral opioid agonist treatment (oOAT), like methadone or buprenorphine, had proven unsuccessful.

But a group of 11 patients enrolled in the government-funded injectable opioid agonist treatment (iOAT) clinics—based in Edmonton and Calgary, and providing supervised hydromorphone injections alongside wrap-around social services—were not going to let their program go down without a fight. (Filter, USA, 03.03.2021)

https://filtermag.org/alberta-injectable-opioid-agonist-treatment/amp/

Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings

Krawczyk, Noa et al.

Journal of Substance Abuse Treatment, Volume 126, 108329 

https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(21)00055-6/fulltext

Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis

Stone, Jack et al.

The Lancet Psychiatry, Volume 0, Issue 0 

https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30538-1/fulltext

Retention in the Austrian opioid agonist treatment system: a national prospective cohort study. 

Busch, M., Klein, C., Uhl, A. et al. 

Harm Reduct J 18, 25 (2021). doi.org/10.1186/s12954-021-00473-9

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-021-00473-9

USA. A state policy option to expanding access to methadone: Utilize Federally Qualified Health Centers

Opioid agonist medications, such as methadone, are an effective treatment option for opioid use disorder. However, they are underutilized as only 20% of individuals with opioid use disorder receive any treatment and only a third of these treated individuals receive opioid use disorder medication. Some of this underutilization is due to access, especially in rural areas. In this study, researchers used an innovative geo-mapping technique to examine whether a recent state policy in Ohio that allows certain facilities – Federally Qualified Health Centers – to dispense methadone, might enhance access by serving as extensions to Opioid Treatment Programs. (Recovery Research Institue, USA, Februar 2021)

https://www.recoveryanswers.org/research-post/state-policy-option-expand-methadone-access-use-qualified-health-centers/

EMCDDA. Balancing access to opioid substitution treatment (OST) with preventing the diversion of opioid substitution medications in Europe: challenges and implications

This report reviews how opioid substitution treatment (OST) is implemented in European countries and examines the public health consequences of the diversion and misuse of prescription OST medications. It looks at how OST medications are diverted to the illicit market, the motivations behind diversion and misuse, and considers the measures to prevent diversion and how they must ensure that the treatment remains available and accessible for those who need it. (EMCDDA, Lissabon, Februar 2021)

https://www.emcdda.europa.eu/system/files/publications/13547/TD0121046ENN.pdf

Office-Based Addiction Treatment Retention and Mortality Among People Experiencing Homelessness. 

Fine DR, Lewis E, Weinstock K, Wright J, Gaeta JM, Baggett TP. 

JAMA Netw Open. 2021;4(3):e210477. doi:10.1001/jamanetworkopen.2021.0477

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2776968

Opioid use, regulation, and harms in Brazil: a comprehensive narrative overview of available data and indicators. 

Maia LO, Daldegan-Bueno D, Fischer B. 

Subst Abuse Treat Prev Policy. 2021 Jan 26;16(1):12. doi: 10.1186/s13011-021-00348-z. PMID: 33499891; PMCID: PMC7836143.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836143/

Are patients' goals in treatment associated with expected treatment outcomes? Findings from a mixed-methods study on outpatient pharmacological treatment for opioid use disorder. 

Rosic T, Naji L, Panesar B, Chai DB, Sanger N, Dennis BB, Marsh DC, Rieb L, Worster A, Thabane L, Samaan Z. 

BMJ Open. 2021 Jan 12;11(1):e044017. doi: 10.1136/bmjopen-2020-044017. PMID: 33436476; PMCID: PMC7805377.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805377/

Core outcomes set for research on the treatment of opioid use disorder (COS-OUD): the National Institute on Drug Abuse Clinical Trials Network protocol for an e-Delphi consensus study. 

Karnik NS, Campbell CI, Curtis ME, Fiellin DA, Ghitza U, Hefner K, Hser YI, McHugh RK, Murphy SM, McPherson SM, Moran L, Mooney LJ, Wu LT, Shmueli-Blumberg D, Shulman M, Schwartz RP, Stephens KA, Watkins KE, Marsden J. 

Trials. 2021 Jan 28;22(1):102. doi: 10.1186/s13063-021-05051-9. PMID: 33509278; PMCID: PMC7841754.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841754/

Treatment Retention in Older Versus Younger Adults with Opioid Use Disorder: A Retrospective Cohort Analysis from a Large Single Center Treatment Program. 

Francis AG, Croll J, Vaishnav H, Langdon K, Beaudoin FL. 

R I Med J (2013). 2021 Feb 1;104(1):51-54. PMID: 33517601.

http://rimed.org/rimedicaljournal/2021/02/2021-02-51-contribution-francis.pdf